Cargando…

DRESS syndrome as a complication of treatment of hepatitis C virus-associated post-inflammatory liver cirrhosis with peginterferon α2a and ribavirin

Various skin and systemic symptoms may develop as a complication of treatment with different medications and medicinal substances. One of them is a relatively rare drug reaction with eosinophilia and systemic symptoms, referred to as DRESS syndrome. The morphology of skin lesions and the patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janocha-Litwin, Justyna, Pazgan-Simon, Monika, Simon, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293381/ https://www.ncbi.nlm.nih.gov/pubmed/25610356 http://dx.doi.org/10.5114/pdia.2014.40939

Ejemplares similares

The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2016)

Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature
por: Pazgan-Simon, Monika, et al.
Publicado: (2015)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

The risk of complications of endoscopic procedures in patients with liver cirrhosis
por: Simon, Krzysztof, et al.
Publicado: (2017)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin
por: Pawlowski, Tomasz, et al.
Publicado: (2021)

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C
por: Masaki, Naohiko, et al.
Publicado: (2014)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Severe chronic atopic dermatitis improvement after hepatitis C virus elimination with sofosbuvir/ledipasvir treatment
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2022)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C
por: Hwang, Yong, et al.
Publicado: (2015)

Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
por: Jung, Chang Ho, et al.
Publicado: (2016)

Neurological Disorders of Patients Living with HIV Hospitalized in Infectious Departments of the Specialist Hospital in Lower Silesia in Poland
por: Janocha-Litwin, Justyna, et al.
Publicado: (2022)

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
por: Yang, Suh Yoon, et al.
Publicado: (2015)

HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV)
por: Pawlowski, Tomasz, et al.
Publicado: (2023)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
por: Ide, Kazuki, et al.
Publicado: (2016)

Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
por: Alsiö, Åsa, et al.
Publicado: (2012)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon α-2a and Ribavirin
por: Kondo, M., et al.
Publicado: (2011)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report
por: Zuwała-Jagiełło, Jolanta, et al.
Publicado: (2015)

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2017)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience
por: Al Ashgar, Hamad, et al.
Publicado: (2008)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report
por: EL-Atrebi, Kamal, et al.
Publicado: (2009)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma
por: Pazgan-Simon, Monika, et al.
Publicado: (2020)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
por: Foster, Graham R., et al.
Publicado: (2016)

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
por: Bernstein, David, et al.
Publicado: (2019)

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
por: Kwon, Jung Hyun, et al.
Publicado: (2009)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5cit17gcls51e9j0rh25264g2n